Interleukin-3 receptor signaling is a driver of myeloid leukaemia and a significant therapeutic target [ 2016 - ]

Research Grant

Researchers: A/Pr Paul Ekert (Principal investigator) ,  Dr Gabriela Brumatti ,  Dr Hayley Ramshaw

Brief description Acute Myeloid Leukaemia (AML) is an aggressive blood cancer. There are many types of AML, but overall, less than half of those with AML are cured. This project evaluates how certain molecules on the surfaces of leukaemic cells keep those cells alive and growing. We are also testing new ways to block these molecules and so provide new therapies for this cancer.

Funding Amount $601,966.00

Funding Scheme Project Grants

Notes Standard Project Grant